Trajectories of brain loss in aging and the development of cognitive impairment

N. E. Carlson, M. M. Moore, A. Dame, D. Howieson, L. C. Silbert, J. F. Quinn, J. A. Kaye

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

BACKGROUND: The use of volumetric MRI as a biomarker for assessing transitions to dementia presumes that more rapid brain loss marks the clinical transition from benign aging to mild cognitive impairment (MCI). The trajectory of this volume loss relative to the timing of the clinical transition to dementia has not been established. METHODS: The authors annually evaluated 79 healthy elderly subjects for up to 15 consecutive years with standardized clinical examinations and volumetric brain MRI assessments of ventricular volume. During the study period, 37 subjects developed MCI. A mixed effects model with a change point modeled the pattern of brain volume loss in healthy aging compared with subjects diagnosed with MCI. RESULTS: The brain loss trajectory of subjects developing MCI during follow-up differed from healthy aging in a two-phase process. First, the annual rate of expansion of ventricular volume decreased with age; however, the annual rates of expansion were greater in those who developed cognitive impairment during follow-up compared with those who did not. Further, subjects who developed MCI had an acceleration of ventricular volume expansion approximately 2.3 years prior to clinical diagnosis of MCI. CONCLUSIONS: Ventricular expansion is faster in those developing mild cognitive impairment years prior to clinical symptoms, and eventually a more rapid expansion occurs approximately 24 months prior to the emergence of clinical symptoms. These differential rates of preclinical atrophy suggest that there are specific windows for optimal timing of introduction of dementia prevention therapies in the future.

Original languageEnglish (US)
Pages (from-to)828-833
Number of pages6
JournalNeurology
Volume70
Issue number11
DOIs
StatePublished - Mar 2008

Fingerprint

Brain
Dementia
Cognitive Dysfunction
Atrophy
Healthy Volunteers
Biomarkers
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Trajectories of brain loss in aging and the development of cognitive impairment. / Carlson, N. E.; Moore, M. M.; Dame, A.; Howieson, D.; Silbert, L. C.; Quinn, J. F.; Kaye, J. A.

In: Neurology, Vol. 70, No. 11, 03.2008, p. 828-833.

Research output: Contribution to journalArticle

Carlson, N. E. ; Moore, M. M. ; Dame, A. ; Howieson, D. ; Silbert, L. C. ; Quinn, J. F. ; Kaye, J. A. / Trajectories of brain loss in aging and the development of cognitive impairment. In: Neurology. 2008 ; Vol. 70, No. 11. pp. 828-833.
@article{b1c0df157376439797fa35f818ad2256,
title = "Trajectories of brain loss in aging and the development of cognitive impairment",
abstract = "BACKGROUND: The use of volumetric MRI as a biomarker for assessing transitions to dementia presumes that more rapid brain loss marks the clinical transition from benign aging to mild cognitive impairment (MCI). The trajectory of this volume loss relative to the timing of the clinical transition to dementia has not been established. METHODS: The authors annually evaluated 79 healthy elderly subjects for up to 15 consecutive years with standardized clinical examinations and volumetric brain MRI assessments of ventricular volume. During the study period, 37 subjects developed MCI. A mixed effects model with a change point modeled the pattern of brain volume loss in healthy aging compared with subjects diagnosed with MCI. RESULTS: The brain loss trajectory of subjects developing MCI during follow-up differed from healthy aging in a two-phase process. First, the annual rate of expansion of ventricular volume decreased with age; however, the annual rates of expansion were greater in those who developed cognitive impairment during follow-up compared with those who did not. Further, subjects who developed MCI had an acceleration of ventricular volume expansion approximately 2.3 years prior to clinical diagnosis of MCI. CONCLUSIONS: Ventricular expansion is faster in those developing mild cognitive impairment years prior to clinical symptoms, and eventually a more rapid expansion occurs approximately 24 months prior to the emergence of clinical symptoms. These differential rates of preclinical atrophy suggest that there are specific windows for optimal timing of introduction of dementia prevention therapies in the future.",
author = "Carlson, {N. E.} and Moore, {M. M.} and A. Dame and D. Howieson and Silbert, {L. C.} and Quinn, {J. F.} and Kaye, {J. A.}",
year = "2008",
month = "3",
doi = "10.1212/01.wnl.0000280577.43413.d9",
language = "English (US)",
volume = "70",
pages = "828--833",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Trajectories of brain loss in aging and the development of cognitive impairment

AU - Carlson, N. E.

AU - Moore, M. M.

AU - Dame, A.

AU - Howieson, D.

AU - Silbert, L. C.

AU - Quinn, J. F.

AU - Kaye, J. A.

PY - 2008/3

Y1 - 2008/3

N2 - BACKGROUND: The use of volumetric MRI as a biomarker for assessing transitions to dementia presumes that more rapid brain loss marks the clinical transition from benign aging to mild cognitive impairment (MCI). The trajectory of this volume loss relative to the timing of the clinical transition to dementia has not been established. METHODS: The authors annually evaluated 79 healthy elderly subjects for up to 15 consecutive years with standardized clinical examinations and volumetric brain MRI assessments of ventricular volume. During the study period, 37 subjects developed MCI. A mixed effects model with a change point modeled the pattern of brain volume loss in healthy aging compared with subjects diagnosed with MCI. RESULTS: The brain loss trajectory of subjects developing MCI during follow-up differed from healthy aging in a two-phase process. First, the annual rate of expansion of ventricular volume decreased with age; however, the annual rates of expansion were greater in those who developed cognitive impairment during follow-up compared with those who did not. Further, subjects who developed MCI had an acceleration of ventricular volume expansion approximately 2.3 years prior to clinical diagnosis of MCI. CONCLUSIONS: Ventricular expansion is faster in those developing mild cognitive impairment years prior to clinical symptoms, and eventually a more rapid expansion occurs approximately 24 months prior to the emergence of clinical symptoms. These differential rates of preclinical atrophy suggest that there are specific windows for optimal timing of introduction of dementia prevention therapies in the future.

AB - BACKGROUND: The use of volumetric MRI as a biomarker for assessing transitions to dementia presumes that more rapid brain loss marks the clinical transition from benign aging to mild cognitive impairment (MCI). The trajectory of this volume loss relative to the timing of the clinical transition to dementia has not been established. METHODS: The authors annually evaluated 79 healthy elderly subjects for up to 15 consecutive years with standardized clinical examinations and volumetric brain MRI assessments of ventricular volume. During the study period, 37 subjects developed MCI. A mixed effects model with a change point modeled the pattern of brain volume loss in healthy aging compared with subjects diagnosed with MCI. RESULTS: The brain loss trajectory of subjects developing MCI during follow-up differed from healthy aging in a two-phase process. First, the annual rate of expansion of ventricular volume decreased with age; however, the annual rates of expansion were greater in those who developed cognitive impairment during follow-up compared with those who did not. Further, subjects who developed MCI had an acceleration of ventricular volume expansion approximately 2.3 years prior to clinical diagnosis of MCI. CONCLUSIONS: Ventricular expansion is faster in those developing mild cognitive impairment years prior to clinical symptoms, and eventually a more rapid expansion occurs approximately 24 months prior to the emergence of clinical symptoms. These differential rates of preclinical atrophy suggest that there are specific windows for optimal timing of introduction of dementia prevention therapies in the future.

UR - http://www.scopus.com/inward/record.url?scp=40549142131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40549142131&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000280577.43413.d9

DO - 10.1212/01.wnl.0000280577.43413.d9

M3 - Article

C2 - 18046010

AN - SCOPUS:40549142131

VL - 70

SP - 828

EP - 833

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 11

ER -